NSE: PPLPHARMA · 30 October 2026
- Piramal Pharma has risen 20.22% over 3 trading sessions; today's move is +3.52%.
- Piramal Pharma announced its financial results for the second quarter and half year ended September 30, 2026, reporting a consolidated revenue of ₹2,617 crores, up 28% year-on-year. EBITDA surged 72% YoY to ₹385 crores with margins expanding by over 350 basis points to 14.7%. Management also upgraded its FY27 outlook, anticipating 19% to 20% revenue growth backed by strong execution across CDMO and Complex Hospital Generics segments.
- Trading volume was 2.90 times the 20-day average daily volume.
Piramal Pharma share price: 20.22% rise over 3 trading sessions
Piramal Pharma Ltd. (PPLPHARMA) advanced 3.52% to close at ₹238.91 on Thursday, trading near the upper end of its intraday range between ₹225.95 and ₹240.00.
The stock outperformed broader benchmarks during the trading session, outpacing the Nifty's 0.51% gain and running ahead of the Nifty Pharma sector index, which rose 1.55%. This upward movement comes on the back of strong recent momentum, including a 25.04% return over the past 5 trading days and a 15.68% gain over the past 20 trading days.
While no single new catalyst was released on Thursday, the price action follows the company's recent Q2 and H1 FY27 financial disclosures on October 27, 2026, where it reported a 28% YoY growth in quarterly revenue to ₹2,617 crores and a 72% increase in EBITDA to ₹385 crores alongside an upgraded full-year outlook. Investor discussions also follow the scheduled post-market analyst and investor meet announcements filed with the exchange.
2.66 crore shares traded by 30 October 2026 · 03:25 PM IST. This compares with a 20-day average daily volume of 91.60 lakh shares (2.90 times). The five-day average daily volume was 3.03 crore shares. Separately, the NSE report for 29 October 2026 showed 56.32 lakh shares delivered, representing 21.35% of that day’s traded volume. The same report recorded 203,525 trades.
The stock's 3.52% gain on nearly 2.9 times its 20-day average volume reflects sustained investor interest and strong institutional participation building upon last week's positive Q2 FY27 earnings report and upgraded outlook.
Latest Company Developments
Piramal Pharma announced its financial results for the second quarter and half year ended September 30, 2026, reporting a consolidated revenue of ₹2,617 crores, up 28% year-on-year. EBITDA surged 72% YoY to ₹385 crores with margins expanding by over 350 basis points to 14.7%. Management also upgraded its FY27 outlook, anticipating 19% to 20% revenue growth backed by strong execution across CDMO and Complex Hospital Generics segments.
The earnings update provides underlying fundamental context for valuation and institutional sentiment following robust operational performance across all business verticals.
The company announced that its commercial arrangement providing sales and distribution support services to Bayer Pharmaceuticals Private Limited is scheduled to expire on December 31, 2026, and will not be renewed. Piramal Pharma clarified that the arrangement accounts for less than 5% of consolidated revenue and operates on a commission basis, expecting no material impact on overall profitability or financial position.
It updates investors on upcoming distribution changes while quantifying the limited financial exposure associated with the non-renewal.
Piramal Pharma completed its acquisition of a controlling equity stake in Yapan Bio Private Limited, executing a previously disclosed call option. This move is aimed at strengthening the company's differentiated biologics capabilities and expanding its advanced CDMO service offerings.
Strategic acquisitions enhance specialized manufacturing capabilities, supporting long-term growth initiatives in high-value biopharma segments.
a press release dated October 27, 2026, titled "Piramal Pharma Limited Announces Results for Q2 and H1 FY2".
The exchange sought clarification from the company regarding a recent media report. Such a request is a verification step and does not by itself confirm the reported issue.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 12.71% on 30 September 2026. This compares with 13.18% on 30 June 2026, a change of -0.47 percentage points.
The filing reported 27 MF/UTI holders.
What to Watch Next
- Execution of order inflows and RFP momentum in the CDMO segment through the second half of FY27
- Progress on the integration of the Kenalog acquisition and its contribution to Complex Hospital Generics revenue
- Operational milestones and expansion updates regarding the Lexington facility and Yapan Bio
- Transition planning and business continuity following the impending conclusion of the Bayer distribution agreement in December 2026
Other Dated Coverage
- Piramal Pharma Share Price Today: Rises 16.04% in 2 Trading Sessions | 29 October 2026 — 29 October 2026
- Piramal Pharma Share Price Today: Rises 18.36% in 2 Trading Sessions | 28 October 2026 — 28 October 2026
More Piramal Pharma news and dated analysis →
Frequently Asked Questions
What is the latest Piramal Pharma company news?
Piramal Pharma announced its financial results for the second quarter and half year ended September 30, 2026, reporting a consolidated revenue of ₹2,617 crores, up 28% year-on-year. EBITDA surged 72% YoY to ₹385 crores with margins expanding by over 350 basis points to 14.7%. Management also upgraded its FY27 outlook, anticipating 19% to 20% revenue growth backed by strong execution across CDMO and Complex Hospital Generics segments.
How strong was Piramal Pharma’s trading volume?
2.66 crore shares traded, 2.90 times the 20-day average daily volume. The price and volume data are dated 30 October 2026 · 03:25 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.